Works by Wu, Fengying

Results: 57
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.

    Published in:
    International Journal of Cancer, 2019, v. 144, n. 10, p. 2605, doi. 10.1002/ijc.31962
    By:
    • Jiang, Tao;
    • Chu, Qian;
    • Wang, Huijuan;
    • Zhou, Fei;
    • Gao, Guanghui;
    • Chen, Xiaoxia;
    • Li, Xuefei;
    • Zhao, Chao;
    • Xu, Qinghua;
    • Li, Wei;
    • Wu, Fengying;
    • Xiong, Anwen;
    • Zhao, Jing;
    • Xu, Yaping;
    • Su, Chunxia;
    • Ren, Shengxiang;
    • Zhou, Caicun;
    • Hirsch, Fred R.
    Publication type:
    Article
    34
    35

    Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2019, v. 10, n. 4, p. 686, doi. 10.1111/1759-7714.12986
    By:
    • Pan, Yingying;
    • Gao, Guanghui;
    • Chen, Xiaoxia;
    • Tian, Qinrui;
    • Wu, Fengying;
    • Liu, Qian;
    • Wang, Yan;
    • Jiang, Tao;
    • Liu, Yiwei;
    • Li, Xuefei;
    • Yang, Shuo;
    • Xu, Chuan;
    • Su, Chunxia;
    • Zhou, Fei;
    • Ren, Shengxiang;
    • Zhou, Caicun
    Publication type:
    Article
    36
    37
    38
    39
    40

    Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy.

    Published in:
    Cancer Communications, 2022, v. 42, n. 12, p. 1331, doi. 10.1002/cac2.12383
    By:
    • Wu, Fengying;
    • Jiang, Tao;
    • Chen, Gongyan;
    • Huang, Yunchao;
    • Zhou, Jianying;
    • Lin, Lizhu;
    • Feng, Jifeng;
    • Wang, Zhehai;
    • Shu, Yongqian;
    • Shi, Jianhua;
    • Hu, Yi;
    • Wang, Qiming;
    • Cheng, Ying;
    • Chen, Jianhua;
    • Lin, Xiaoyan;
    • Wang, Yongsheng;
    • Huang, Jianan;
    • Cui, Jiuwei;
    • Cao, Lejie;
    • Liu, Yunpeng
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

    Published in:
    Lung Cancer: Targets & Therapy, 2024, v. 15, p. 87, doi. 10.2147/LCTT.S463429
    By:
    • Ou, Sai-Hong Ignatius;
    • Le, Xiuning;
    • Nagasaka, Misako;
    • Reungwetwattana, Thanyanan;
    • Ahn, Myung-Ju;
    • Lim, Darren WT;
    • Santos, Edgardo S;
    • Shum, Elaine;
    • Lau, Sally CM;
    • Lee, Jii Bum;
    • Calles, Antonio;
    • Wu, Fengying;
    • Lopes, Gilberto;
    • Sriuranpong, Virote;
    • Tanizaki, Junko;
    • Horinouchi, Hidehito;
    • Garassino, Marina C;
    • Popat, Sanjay;
    • Besse, Benjamin;
    • Rosell, Rafael
    Publication type:
    Article
    50